Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.

Literature DB >> 26270186

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy.

Jennifer A Lo¹, David E Fisher², Keith T Flaherty³.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 26270186 PMCID： PMC4679487 DOI： 10.1001/jamaoncol.2015.2274

Source DB: PubMed Journal: JAMA Oncol ISSN： 2374-2437 Impact factor: 31.777

× No keyword cloud information.

7 in total

1. Improved survival with ipilimumab in patients with metastatic melanoma.

Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245

2. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.

Authors: G Q Phan; P Attia; S M Steinberg; D E White; S A Rosenberg
Journal: J Clin Oncol Date: 2001-08-01 Impact factor: 44.544

3. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245

Review 4. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.

Authors: Hansje-Eva Teulings; Jacqueline Limpens; Sophia N Jansen; Aeilko H Zwinderman; Johannes B Reitsma; Phyllis I Spuls; Rosalie M Luiten
Journal: J Clin Oncol Date: 2015-01-20 Impact factor: 44.544

5. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

Authors: Martina Sanlorenzo; Igor Vujic; Adil Daud; Alain Algazi; Matthew Gubens; Sara Alcántara Luna; Kevin Lin; Pietro Quaglino; Klemens Rappersberger; Susana Ortiz-Urda
Journal: JAMA Dermatol Date: 2015-11 Impact factor: 10.282

6. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.

Authors: M B Atkins; J W Mier; D R Parkinson; J A Gould; E M Berkman; M M Kaplan
Journal: N Engl J Med Date: 1988-06-16 Impact factor: 91.245

7. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors: Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal: N Engl J Med Date: 2013-06-02 Impact factor: 91.245

7 in total

25 in total

Review 1. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors: Xue Bai; David E Fisher; Keith T Flaherty
Journal: Nat Rev Clin Oncol Date: 2019-09 Impact factor: 66.675

2. Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

Authors: Mari Aso; Yukihiro Toi; Jun Sugisaka; Tomoiki Aiba; Sachiko Kawana; Ryohei Saito; Takahiro Ogasawara; Kyoji Tsurumi; Kana Ono; Hisashi Shimizu; Yutaka Domeki; Keisuke Terayama; Yosuke Kawashima; Atsushi Nakamura; Shinsuke Yamanda; Yuichiro Kimura; Yoshihiro Honda; Shunichi Sugawara
Journal: Oncologist Date: 2019-11-07

Review 3. Management of the cutaneous adverse effects of antimelanoma therapy.

Authors: Rose Congwei Liu; Germana Consuegra; Pablo Fernández-Peñas
Journal: Melanoma Manag Date: 2017-11-22

Review 4. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors: Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal: Curr Treat Options Oncol Date: 2020-03-19

5. Supportive care for patients undergoing immunotherapy.

Authors: Bernardo Leon Rapoport; Ronwyn van Eeden; Vincent Sibaud; Joel B Epstein; Jean Klastersky; Matti Aapro; Devan Moodley
Journal: Support Care Cancer Date: 2017-07-13 Impact factor: 3.603

Review 6. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.

Authors: Petros Fessas; Lucia A Possamai; James Clark; Ella Daniels; Cathrin Gudd; Benjamin H Mullish; James L Alexander; David J Pinato
Journal: Immunology Date: 2019-11-19 Impact factor: 7.397

7. Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.